MIRA PHARMACEUTICALS, INC. - 8-K Filing

MIRA Pharmaceuticals reports positive proof-of-concept results for oral obesity candidate SKNY-1 in mouse models. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Other Exhibits)

SEC EDGAR ·

Tickers: $MIRA

Read the full article at SEC EDGAR

More Regulatory news